Form 4: Oramed Director Reznick Granted 36,250 RSUs

Oramed Pharmaceuticals Director Yehuda Reznick received grants of 36,250 Restricted Stock Units, vesting over future periods.

Summary

• Director Yehuda Reznick was granted 30,000 Restricted Stock Units (RSUs) on December 31, 2025.
• These 30,000 RSUs will vest ratably in three annual tranches, with the first vesting commencing on January 1, 2027.
• An additional 6,250 RSUs were granted to Director Reznick on December 31, 2025.
• These 6,250 RSUs will vest in quarterly installments over a one-year period, beginning on April 1, 2026.
• Each RSU represents the right to receive one share of Oramed Pharmaceuticals Inc. common stock.
• Following these reported transactions, Director Reznick beneficially owns 105,180 shares directly.

Sentiment

Score: 6

Explanation: The filing reports routine compensation in the form of Restricted Stock Units to a director, which is generally viewed as a positive for aligning management incentives with shareholder interests, though it does not represent a new strategic development or financial performance update.

Positives

• The RSU grants align Director Yehuda Reznick's long-term interests with those of Oramed Pharmaceuticals' shareholders.
• Equity-based compensation is a common practice to incentivize key personnel and retain talent.

Negatives

• The vesting of these RSUs will result in a minor dilution of existing shareholder equity over time as new shares are issued.

Future Outlook

The grants of Restricted Stock Units indicate a future commitment to the director, with vesting schedules extending into 2026 and 2027, aligning the director's incentives with the company's long-term performance.

Industry Context

The granting of Restricted Stock Units to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages to attract and retain talent while aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• RSU grants are a common form of equity compensation across publicly traded companies, particularly in growth-oriented sectors like pharmaceuticals, comparable to practices at companies such as Pfizer, Moderna, or Eli Lilly, which frequently use similar mechanisms to incentivize their leadership.

Stakeholder Impact

• Shareholders: Potential minor dilution upon RSU vesting, but improved alignment of director's interests with long-term company performance.
• Director (Yehuda Reznick): Future equity compensation tied to company stock performance.

Next Steps

• The company will issue shares of common stock to Director Reznick upon the vesting of the RSUs according to the specified schedules starting April 1, 2026, and January 1, 2027.

Key Dates

Recommendation

This Form 4 filing details routine compensation for a director through Restricted Stock Units. While it aligns the director's interests with long-term shareholder value, it does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation based solely on this filing.

Keywords

Oramed Pharmaceuticals, ORMP, Restricted Stock Units, RSU, Insider Ownership, Director Compensation, Equity Grant, Stock Award